Argenx is acquiring Forte Biosciences for $2.2 billion in cash, primarily for FB102, a CD122-targeting asset with promising Phase 1b data in vitiligo and celiac disease. This acquisition significantly expands Argenx's immunology pipeline and is a major strategic move for both companies.
Argenx is acquiring Forte Biosciences for approximately $2.2 billion in cash, valuing Forte at $77 per share. This transaction is a major corporate catalyst, as it significantly expands Argenx's immunology portfolio with FB102, a CD122-targeting asset that has shown positive Phase 1b results in vitiligo and celiac disease. For Argenx, this represents a strategic move to fuel long-term growth by accessing novel biology and addressing diseases with high unmet needs. For Forte Biosciences, it's a clear positive, as shareholders will receive a substantial premium. The short-term implication for Forte is a significant stock price surge, while for Argenx, it's an investment that could lead to long-term pipeline strength, though it carries integration and development risks. Traders should watch for Argenx's investor call for further details on the strategic rationale and financial implications.